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Figure	
  5.3:	
  Certain	
  dysferlin	
  missense	
  mutations	
  are	
  intrinsically	
  biologically	
  active.	
  	
  (A)	
   COS-­‐7	
   cells	
   were	
   transfected	
   with	
   GFP,	
   WT,	
   dysferlin∆C2F,	
   dysferlinV374L	
   or	
  dysferlinD1837N.	
   Western	
   blots	
   of	
   protein	
   extracts	
   were	
   stained	
   with	
   anti-­‐dysferlin	
  antibodies,	
  and	
  with	
  anti-­‐ubiquitin	
  antibodies	
  as	
  positive	
  control	
  for	
  Velcade	
  treatment	
  efficacy.	
  Anti-­‐alpha-­‐tubulin	
  antibodies	
  were	
  used	
  as	
  a	
  loading	
  control.	
  (B)	
  Quantification	
  of	
  dysferlin	
  content	
  over	
  alpha-­‐tubulin	
  levels.	
  *	
  p<0.05.	
  (C)	
  Immunostaining	
  against	
  the	
  extracellular	
   c-­‐myc	
   epitope	
   on	
   the	
   dysferlin	
   construct	
   (red)	
   in	
   ULM1/01	
   myoblasts	
  transfected	
   with	
   GFP,	
   WT,	
   dysferlin∆C2F,	
   dysferlinV374L	
   or	
   dysferlinD1837N.	
  Immunostaining	
   against	
   GFP	
   (green)	
   demonstrates	
   cellular	
   expression	
   of	
   each	
  construct.	
  Lower	
  panel	
  showing	
  c-­‐myc	
  staining	
  only	
   is	
   included	
  to	
  better	
  visualize	
  the	
  plasma	
  membrane	
  staining.	
  Scale	
  bar	
  =	
  10	
  μm.	
   (D)	
  Quantification	
  of	
  plasmalemmally-­‐inserted	
   dysferlin	
   (c-­‐myc)	
   over	
   dysferlin	
   content	
   (GFP)	
   *	
   p<0.05.	
   Error	
   bars	
   are	
  reported	
   as	
  mean	
   +	
   SEM.	
   (E)	
   Plasma	
  membrane	
   repair	
   assay	
   was	
   performed	
   on	
   the	
  dysferlin-­‐deficient	
   myoblast	
   culture	
   ULM1/01	
   transfected	
   with	
   GFP,	
   WT,	
  dysferlinV374L	
  or	
  dysferlinD1837N.	
  Relative	
   fluorescence	
   intensity	
   (∆F/F0)	
  over	
   time	
  following	
   laser-­‐induced	
   injury	
   is	
   represented	
   as	
   means	
   +	
   standard	
   deviation.	
   *	
  p<0.0005,	
  resealing	
  kinetics	
  are	
  significantly	
  different	
  from	
  WT	
  resealing	
  kinetics.	
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Table	
  5.	
  1:	
  Primers	
  used	
  for	
  missense	
  mutated	
  dysferlin	
  constructs	
  	
  
	
  	
  	
  
	
  
	
   	
  
Dysferlin	
  missense	
  mutation	
   Sequence	
  of	
  oligonucleotides	
  (oligo)	
  R555W	
   Forward:	
  5'-­‐GCT	
  TAT	
  CGT	
  GGC	
  TGG	
  CTT	
  CTG	
  CTC	
  TCC-­‐3'	
  Reverse:	
  5'-­‐CAG	
  GGA	
  GAG	
  CAG	
  AAG	
  CCA	
  GCC	
  ACG	
  ATA	
  AGC-­‐3'	
  V374L	
   Forward:	
  5'-­‐	
  GCCCACAGGCCTAGCCCTGCGAGGAG	
  -­‐3'	
  Reverse:	
  5'-­‐	
  CTCCTCGCAGGGCTAGGCCTGTGGGC	
  -­‐3'	
  R959W	
   Forward:	
  5'-­‐	
  GAG	
  AAC	
  CAG	
  ACC	
  TGG	
  CTT	
  CCC	
  GGA	
  GGC	
  CAG	
  -­‐3'	
  Reverse:	
  5'-­‐	
  	
  CTG	
  GCC	
  TCC	
  CGG	
  AAG	
  CCA	
  GGT	
  CTG	
  GTT	
  CTC	
  -­‐3'	
  P1970S	
   Forward:	
  5'-­‐	
  GAAGGGCTGGTGGTCCTGTGTAGCAGAAGAG	
  -­‐3'	
  Reverse:	
  5'-­‐	
  	
  CTCTTCTGCTACACAGGACCACCAGCCCTTC	
  -­‐3'	
  D1837N	
   Forward:	
  5'-­‐	
  GAGAAGATGAGCAACATTTATGTGAAAGGTTG	
  -­‐3'	
  Reverse:	
  5'-­‐	
  	
  CAACCTTTCACATAAATGTTGCTCATCTTCTC	
  -­‐3'	
  R2042C	
   Forward:	
  5'-­‐	
  ATC	
  CTG	
  TGG	
  CGG	
  TGT	
  TTC	
  CGG	
  TGG	
  GCC	
  ATC	
  -­‐3'	
  Reverse:	
  5'-­‐	
  	
  GAT	
  GGC	
  CCA	
  CCG	
  GAA	
  ACA	
  CCG	
  CCA	
  CAG	
  GAT	
  -­‐3'	
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CHAPTER	
  6	
  	
  	
  
6 General	
  Discussion	
  	
   	
  
	
   132	
  
Dysferlinopathies	
   are	
   an	
   incurable	
   recessively	
   inherited	
   form	
   of	
   muscular	
   dystrophy	
  with	
   a	
   serious	
   personal	
   and	
   socio-­‐economic	
   impact.	
   Finding	
   treatments	
   or	
   a	
   cure	
   for	
  dysferlinopathies	
  is	
  imperative.	
  	
  At	
   the	
  commencement	
  of	
   this	
   thesis,	
   the	
  only	
  clinical	
   treatments	
   for	
  dysferlinopathies	
  were	
   symptomatic,	
   primarily	
   through	
   anti-­‐inflammatory	
   medications,	
   which	
   often	
  aggravated	
  the	
  disease	
  rather	
  than	
  relieved	
  the	
  symptoms.	
  Research	
  into	
  exon	
  skipping	
  for	
   dysferlinopathies	
   was	
   in	
   its	
   infancy	
   (Wein	
   et	
   al.,	
   2010),	
   adeno-­‐associated	
   viral	
  therapies	
  using	
  full-­‐length	
  dysferlin	
  were	
  not	
  very	
  promising	
  (Lostal	
  et	
  al.,	
  2010),	
  and	
  a	
  naturally	
   occurring	
   minidysferlin	
   provided	
   proof-­‐of-­‐principle	
   potential	
   for	
  minidysferlin	
  design	
  (Krahn	
  et	
  al.,	
  2010).	
  	
  To	
   understand	
   how	
   a	
   gene	
   leads	
   to	
   the	
   disease,	
   one	
   must	
   understand	
   its	
   biological	
  mechanisms	
   in	
   order	
   to	
   gain	
   insight	
   as	
   to	
   how	
  molecular	
   alterations	
   can	
   lead	
   to	
   the	
  pathology.	
  Dysferlin’s	
   role	
   in	
   the	
  membrane	
  patch	
   repair	
   complex	
  was	
   acknowledged	
  within	
  five	
  years	
  of	
   its	
  discovery	
  in	
  1998	
  (Bansal	
  et	
  al.,	
  2003).	
  However	
  it	
  was	
  only	
  in	
  2006	
  that	
  dysferlin	
   ’s	
  role	
  was	
  expanded	
  to	
  include	
  myogenesis	
  (de	
  Luna	
  et	
  al.,	
  2006).	
  At	
   the	
  onset	
   of	
   this	
   study,	
   dysferlin	
  was	
   also	
   implicated	
   in	
   calcium	
  signaling	
   (Covian-­‐Nares	
  et	
  al.,	
  2010),	
  endothelial	
  cell	
  adhesion	
  and	
  angiogenesis	
  (Sharma	
  et	
  al.,	
  2010)	
  and	
  endothelial	
  trafficking	
  of	
  membrane	
  bound	
  proteins	
  (Leung	
  et	
  al.,	
  2011).	
  	
  This	
  study	
  investigated	
  the	
  molecular	
  biology	
  of	
  dysferlin’s	
  C2	
  domains,	
  plasmalemmal	
  localization,	
   membrane	
   repair	
   function,	
   degradation	
   pathway	
   and	
   involvement	
   in	
  myogenesis.	
   Insights	
   gleaned	
   from	
   these	
   studies	
   led	
   to	
   the	
   rational	
   design	
   of	
  minidysferlins	
   suitable	
   for	
   AAV	
   encapsidation,	
   a	
   novel	
   pharmacological	
   treatment	
  option	
   and	
   further	
   validation	
   for	
   exon	
   skipping	
   strategies	
   for	
   the	
   treatment	
   of	
  dysferlinopathies.	
  	
  
6.1 Objectives	
  and	
  Summary	
  of	
  the	
  Results	
  	
  The	
  following	
  summarizes	
  the	
  results	
  and	
  conclusions	
  made	
  according	
  to	
  the	
  objectives	
  laid	
  out	
  in	
  Chapter	
  1.	
  	
  	
  
	
   133	
  
6.1.1 The	
  dysferlin,	
  alpha-­‐tubulin,	
  HDAC6	
  triad	
  interaction	
  provides	
  insights	
  into	
  
microtubule	
  acetylation	
  and	
  myogenesis	
  in	
  muscle	
  cells	
  	
  
Objective	
  I	
  -­‐	
  To	
  determine	
  the	
  significance	
  of	
  dysferlin’s	
  interaction	
  with	
  alpha-­‐tubulin,	
  as	
  
was	
  previously	
  described	
  by	
  our	
  research	
  group	
  following	
  a	
  liquid-­‐chromatography-­‐mass	
  
spectrometry	
  analysis	
  of	
  the	
  dysferlin	
  interactome.	
  	
  Shortly	
   before	
   the	
   onset	
   of	
   this	
   thesis	
   study,	
   our	
   research	
   group	
   had	
   used	
   liquid-­‐chromatography-­‐tandem	
  mass	
  spectrometry	
  to	
  characterize	
  the	
  dysferlin	
  interactome.	
  A	
   candidate	
   dysferlin	
   binding	
   partner,	
   alpha-­‐tubulin,	
   was	
   shown	
   to	
   interact	
   with	
  dysferlin	
   in	
   its	
   soluble	
   (monomeric	
   tubulin)	
   and	
   polymerized	
   (microtubule)	
   forms	
  (Azakir	
   et	
   al.,	
   2010).	
   Microtubules	
   are	
   highly	
   modified,	
   for	
   instance	
   by	
   acetylation,	
  which	
   led	
   us	
   to	
   our	
   study	
   of	
   HDAC6,	
   the	
   alpha-­‐tubulin	
   deacetylating	
   enzyme,	
   as	
   a	
  potential	
  companion	
  protein	
  to	
  this	
  interaction.	
  	
  This	
  study	
  identified	
  HDAC6	
  as	
  a	
  novel	
  dysferlin	
   interacting	
  protein	
  and	
  showed	
   the	
   importance	
  of	
  dysferlin’s	
  C2	
  domains	
  as	
  protein	
  binding	
  modules	
   for	
   this	
   triad	
   interaction:	
  binding	
  HDAC6	
  via	
   its	
  C2D	
  domain	
  and	
  binding	
  alpha-­‐tubulin	
  via	
  its	
  C2A	
  and	
  C2B	
  domains.	
  	
  	
  We	
  showed	
   that	
  dysferlin	
  expression	
   increased	
   the	
  alpha-­‐tubulin	
  acetylation	
   levels	
   in	
  muscle	
   cells.	
   Increased	
   microtubule	
   acetylation	
   promotes	
   microtubule	
   stability,	
   as	
  demonstrated	
   by	
   increased	
   resistance	
   to	
   Nocodazole-­‐induced	
   depolymerization	
   and	
  cold-­‐induced	
   depolymerization	
   in	
   the	
   dysferlin-­‐expressing	
   muscle	
   cells.	
   Dysferlin	
  expression	
  also	
  promoted	
  faster	
  microtubule	
  recovery	
  from	
  depolymerization,	
  resulting	
  in	
   more	
   microtubules	
   being	
   repolymerized,	
   stabilized	
   and	
   consequently	
   post-­‐translationally	
  modified	
  by	
  acetylation.	
  These	
  results	
  suggest	
  that	
  dysferlin	
  may	
  act	
  as	
  an	
  inhibitor	
  of	
  HDAC6-­‐mediated	
  microtubule	
  acetylation	
  in	
  muscle	
  cells.	
  	
  	
  Given	
   that	
  differentiated	
  muscle	
  cells	
  express	
  higher	
   levels	
  of	
  microtubule	
  acetylation	
  than	
   undifferentiated	
   myoblasts,	
   we	
   studied	
   the	
   effect	
   of	
   increased	
   microtubule	
  acetylation	
  on	
  muscle	
  cell	
  differentiation	
  in	
  dysferlin-­‐expressing	
  cells	
  using	
  the	
  HDAC6	
  inhibitor	
   Tubastatin.	
   Results	
   showed	
   that	
   when	
   HDAC6	
   was	
   inhibited	
   early	
   during	
  differentiation,	
   myotube	
   formation	
   was	
   impaired.	
   Conversely,	
   HDAC6	
   inhibition	
   in	
  differentiated	
  myotubes	
  promoted	
  myotube	
  elongation.	
  Given	
  that	
  dysferlin	
  expression	
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is	
   upregulated	
   during	
   myotube	
   formation,	
   these	
   results	
   suggest	
   that	
   temporal	
  regulation	
  of	
  dysferlin	
  may	
  be	
  important	
  for	
  proper	
  myogenesis.	
  Specifically,	
  that	
  later	
  expression	
   of	
   dysferlin	
   would	
   promote	
   myotube	
   formation	
   and	
   elongation	
   through	
  increased	
   microtubule	
   acetylation,	
   whereas	
   early	
   expression	
   of	
   dysferlin	
   would	
  promote	
  premature	
  microtubule	
  hyperacetylation	
  by	
  way	
  of	
   inhibiting	
  HDAC6,	
  which	
  would	
  impair	
  myotube	
  formation.	
  	
  	
  The	
  results	
  would	
  this	
  study	
  would	
  recommend	
  the	
  use	
  of	
  promoters	
  that	
  are	
  expressed	
  at	
   later	
  stages	
  of	
  muscle	
  differentiation,	
  such	
  as	
  C5-­‐12	
  (Spangenburg	
  et	
  al.,	
  2004)	
  and	
  the	
  human	
  α-­‐skeletal	
  actin	
  promoter	
  (Evans	
  et	
  al.,	
  2008),	
  and	
  would	
  caution	
  against	
  the	
  use	
  of	
  promoters	
  expressed	
  early	
  in	
  muscle	
  development,	
  such	
  as	
  CMV	
  and	
  CAG	
  (Evans	
  et	
   al.,	
   2008).	
   This	
   information	
   could	
   be	
   useful	
   in	
   the	
   future	
   development	
   of	
   AAV-­‐encapsidated	
  dysferlin	
  constructs.	
  	
  	
  
6.1.2 Functional	
  redundancy	
  of	
  dysferlin’s	
  C2	
  domains	
  	
  
Objective	
  II	
  –	
  To	
  determine	
  if	
  there	
  is	
  functional	
  redundancy	
  between	
  dysferlin’s	
  seven	
  C2	
  
domains	
  in	
  their	
  ability	
  to	
  localize	
  to	
  and	
  repair	
  the	
  muscle	
  plasma	
  membrane.	
  	
  Characterization	
  of	
  dysferlin’s	
  C2	
  domains	
  currently	
  consists	
  of	
  calcium	
  dependent	
  and	
  independent	
   phospholipid	
   interactions,	
   specifically	
   with	
   phosphatidylserine,	
  phosphatidylinositol	
   4-­‐phosphate	
   or	
   phosphatidylinositol	
   4,5-­‐bisphosphate	
   (Davis	
   et	
  al.,	
  2002;	
  Therrien	
  et	
  al.,	
  2009).	
  Protein	
  interactions	
  mediated	
  by	
  dysferlin’s	
  C2	
  domains	
  included	
   dysferlin	
   C2A	
   binding	
   to	
   MG53	
   dimers	
   (Matsuda	
   et	
   al.,	
   2012)	
   and	
   AHNAK	
  (Huang	
  et	
  al.,	
  2007);	
  alpha-­‐tubulin	
  binding	
  via	
  dysferlin’s	
  C2A	
  and	
  C2B	
  domains	
  (Azakir	
  et	
  al.,	
  2010);	
  and	
  HDAC6	
  binding	
  to	
  dysferlin’s	
  C2D	
  domain,	
  the	
  latter	
  being	
  the	
  newest	
  addition	
  as	
  demonstrated	
  in	
  Chapter	
  2.	
  	
  In	
   Chapter	
   3,	
   we	
   investigated	
   the	
   functionality	
   of	
   dysferlin’s	
   C2	
   domains	
   for	
  plasmalemmal	
   localization	
   and	
   resealing	
   kinetics	
   by	
   individually	
   deleting	
   each	
   C2	
  domain	
   from	
   a	
   full-­‐length	
   dysferlin	
   construct	
   and	
   transfecting	
   the	
   deleted	
   constructs	
  into	
   dysferlin-­‐deficient	
   cells.	
   This	
   study	
   revealed	
   that	
   dysferlin’s	
   C2A,	
   C2F	
   and	
   C2G	
  domains	
   are	
   essential	
   for	
   correct	
  plasmalemmal	
   localization	
  and	
  efficient	
   resealing	
  of	
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plasmalemmal	
  injuries.	
  However,	
  deletion	
  of	
  dysferlin’s	
  C2B,	
  C2C	
  and	
  C2E	
  domains	
  did	
  not	
   affect	
   plasmalemmal	
   localization	
   and	
   resealing	
   kinetics,	
   indicating	
   that	
   these	
  domains	
   are	
   functionally	
   redundant	
   for	
   at	
   least	
   these	
   two	
   of	
   dysferlin’s	
   functions.	
  Dysferlin’s	
   C2D	
   domain,	
   on	
   the	
   other	
   hand,	
   was	
   not	
   required	
   for	
   plasmalemmal	
  localization,	
   but	
   its	
   deletion	
   affected	
   the	
   resealing	
   kinetics;	
   cells	
   transfected	
  with	
   the	
  GFP-­‐Dysf∆C2D	
  construct	
  did	
  not	
  reseal	
  as	
  efficiently	
  as	
  wildtype	
  dysferlin.	
  It	
  is	
  possible	
  that	
   the	
  C2D	
  domain	
   is	
   required	
   to	
   interact	
  with	
  a	
  membrane	
  repair	
  protein,	
  but	
   this	
  would	
  not	
  seem	
  to	
  be	
  crucial	
  given	
  that	
  mini-­‐dysferlins	
  lacking	
  the	
  C2D	
  domain	
  are	
  still	
  able	
  to	
  efficiently	
  reseal	
  the	
  plasma	
  membrane.	
  	
  	
   	
  
6.1.2.1 Rationale	
  for	
  the	
  pursuit	
  of	
  exon	
  skipping	
  therapy	
  for	
  dysferlinopathies	
  	
  Construction	
  of	
  midi-­‐dysferlins	
  having	
  their	
  C2	
  domains	
  deleted,	
  but	
  without	
  affecting	
  the	
  linker	
  regions	
  between	
  them,	
  demonstrated	
  that	
  multi-­‐C2	
  domain	
  deletions	
  do	
  not	
  impair	
   overall	
   dysferlin	
   function	
   (for	
   plasmalemmal	
   localization	
   and	
   resealing).	
   This	
  suggests	
   that	
  dysferlin’s	
  C2	
  domains	
  are	
   independently	
   folded	
  domains,	
  which	
  agrees	
  with	
  the	
  literature.	
  	
  	
  Furthermore,	
  it	
  suggests	
  that	
  removal	
  of	
  these	
  entire	
  domains	
  would	
  not	
  be	
  pathogenic,	
  which	
   would	
   support	
   the	
   skipping	
   of	
   C2	
   domain-­‐encoding	
   exons.	
   Our	
   study	
   of	
   the	
  functionality	
   of	
   a	
   dysferlin	
   construct	
   lacking	
   its	
   32nd	
   exon,	
   which	
   was	
   based	
   on	
   an	
  observation	
   of	
   a	
   mildly	
   affected	
   dysferlinopathic	
   patient	
   with	
   a	
   natural	
   in	
   frame	
  skipping	
  of	
  the	
  32nd	
  exon	
  (Sinnreich	
  et	
  al.,	
  2006),	
  would	
  further	
  support	
  this	
  notion.	
  As	
  presented	
   in	
   Chapter	
   3,	
   skipping	
   of	
   an	
   exon	
   encoding	
   part	
   of	
   the	
   C2D	
   domain	
   still	
  allowed	
  the	
  truncated	
  construct	
  to	
  localize	
  to	
  the	
  plasma	
  membrane	
  although	
  at	
  lower	
  efficiency	
   than	
   wildtype	
   dysferlin.	
   It	
   did	
   not	
   impair	
   the	
   construct’s	
   ability	
   to	
   repair	
  plasmalemmal	
   disruptions	
   with	
   similar	
   kinetics	
   to	
   wildtype	
   dysferlin,	
   which	
   could	
  correlate	
  with	
  the	
  mild	
  phenotype	
  observed	
  in	
  the	
  patient.	
  	
  	
  Additionally,	
   the	
   demonstration	
   of	
   functionality	
   of	
   the	
   mini-­‐dysferlins	
   presented	
   in	
  Chapter	
  3	
  demonstrated	
   that	
   large	
  deletions	
  of	
   entire	
   coding	
   sequences	
   (for	
   instance,	
  from	
  the	
  C2B	
  domain	
  through	
  to	
  the	
  C2F	
  domain)	
  can	
  be	
  tolerated	
  by	
  the	
  protein.	
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This	
   study	
   supports	
   the	
   rationale	
   for	
   pursuing	
   skipping	
   of	
   exon	
   32	
   as	
   a	
   potential	
  therapeutic	
  strategy	
  for	
  patients	
  harbouring	
  mutations	
  in	
  this	
  particular	
  exon.	
  Coupled	
  with	
  the	
  reports	
  that	
  several	
  of	
  dysferlin’s	
  exons	
  (exons	
  19,	
  24,	
  30,	
  32,	
  34	
  and	
  49)	
  are	
  skippable	
  using	
  antisense	
  oligonucelotides	
  (AONS)	
  (Aartsma-­‐Rus	
  et	
  al.,	
  2010;	
  Santos	
  et	
  al.,	
   2010;	
  Wein	
   et	
   al.,	
   2010),	
   exon	
   skipping	
   for	
   dysferlinopathies	
  will	
   likely	
   become	
   a	
  more	
  prominent	
  topic	
  in	
  the	
  coming	
  years.	
  	
  	
  A	
  consideration	
  to	
  bear	
  in	
  mind	
  is	
  that	
  exon	
  skipping	
  would	
  be	
  an	
  individually	
  tailored	
  therapeutic	
   strategy,	
   given	
   that	
  DYSF	
  mutations	
   are	
   located	
   throughout	
   the	
   gene	
   and	
  that	
   patients	
   often	
   harbour	
   two	
   different	
   pathological	
   alleles	
   (since	
   dysferlinopathies	
  are	
   recessively	
   inherited).	
   Yet,	
   because	
   these	
   diseases	
   are	
   recessively	
   inherited,	
   only	
  one	
  missense-­‐mutated	
  allele	
  would	
  theoretically	
  need	
  to	
  be	
  corrected	
  for.	
  	
  
6.1.2.2 Rationale	
  for	
  the	
  pursuit	
  of	
  AAV-­‐mediated	
  gene	
  therapy	
  for	
  
dysferlinopathies	
  	
  
Objective	
   III	
   –	
  To	
  determine	
   if	
  a	
   small	
  mini-­‐dysferlin	
   can	
  be	
  generated	
   that	
   retains	
   the	
  
functionality	
  of	
   full-­‐length	
  dysferlin,	
  which	
  would	
  be	
  small	
  enough	
  to	
  encapsidate	
  within	
  
an	
  adeno-­‐associated	
  viral	
  vector.	
  	
  The	
  generation	
  of	
  a	
  mini-­‐dysferlin	
  is	
  required	
  for	
  effective	
  AAV-­‐mediated	
  encapsidation.	
  At	
  the	
  onset	
  of	
  this	
  study,	
  it	
  was	
  unclear	
  whether	
  a	
  severely	
  truncated	
  dysferlin	
  protein	
  would	
   still	
   be	
   functional.	
   Within	
   a	
   year	
   of	
   commencing	
   this	
   thesis,	
   Krahn	
   et	
   al	
  demonstrated	
  the	
  in	
  vitro	
  muscle	
  fiber	
  resealing	
  potential	
  of	
  a	
  naturally	
  occurring	
  mini-­‐dysferlin	
  molecule,	
  which	
  encompassed	
  the	
  C2F,	
  C2G	
  and	
  the	
   transmembrane	
  domain	
  (Krahn	
  et	
  al.,	
  2010).	
  	
  	
  Very	
  recently,	
  a	
  study	
  was	
  published	
  demonstrating	
  that	
  it	
  was	
  not	
  full-­‐length	
  dysferlin	
  being	
   recruited	
   to	
   sites	
   of	
   membrane	
   injury.	
   In	
   fact,	
   it	
   was	
   a	
   dysferlin	
   fragment—consisting	
  of	
   the	
  C2F,	
  C2G	
  and	
  transmembrane	
  domain—that	
  was	
  acting	
  at	
   the	
  site	
  of	
  injury.	
  Dr	
  Cooper’s	
  group	
  showed	
  that	
  upon	
  injury,	
  MG53	
  is	
  recruited	
  to	
  and	
  disperses	
  around	
   sites	
   of	
   injury	
   (Lek	
   et	
   al.,	
   2013).	
   Full-­‐length	
   dysferlin	
   is	
   cleaved	
   by	
   calpain,	
  releasing	
  a	
  72	
  kDa	
  C-­‐terminal	
  dysferlin	
  fragment	
  (dysferlin-­‐C72),	
  and	
  vesicles	
  adorned	
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with	
   this	
   minidysferlin	
   accumulated	
   at	
   the	
   site	
   of	
   injury	
   (Lek	
   et	
   al.,	
   2013).	
   Upon	
  dysferlin-­‐C72’s	
   arrival,	
   it	
   and	
  MG53	
   intercalated	
   in	
   a	
   tight	
   ring	
   around	
   the	
   injury	
   site	
  and	
  mediated	
  membrane	
  repair	
  (Lek	
  et	
  al.,	
  2013).	
  	
  	
  Dysferlin-­‐C72	
  and	
  the	
  mini-­‐dysferlin	
  construct	
  from	
  Levy’s	
  group	
  are	
  quite	
  similar,	
  both	
  having	
   dysferlin’s	
   C2F-­‐C2G-­‐TM	
   region.	
   However,	
   Levy’s	
   mini-­‐dysferlin	
   construct	
   was	
  unable	
  to	
  alleviate	
  the	
  muscular	
  dystrophy	
  phenotype	
  of	
  dysferlin-­‐deficient	
  mice	
  in	
  vivo	
  (Lostal	
  et	
  al.,	
  2012).	
  Notably,	
  this	
  construct	
  lacked	
  the	
  C2A	
  domain,	
  which	
  the	
  results	
  of	
  Chapter	
  3	
   showed	
   to	
  be	
   required	
   for	
  plasma	
  membrane	
   localization	
  and	
   resealing,	
   as	
  well	
  as	
   for	
  calcium	
  dependent	
  phospholipid	
  binding	
  and	
  multiple	
  protein	
   interactions	
  as	
  demonstrated	
   in	
  previous	
  studies	
  by	
  our	
   laboratory	
  and	
  others	
   (Davis	
  et	
  al.,	
  2002;	
  Huang	
  et	
  al.,	
  2007;	
  Therrien	
  et	
  al.,	
  2009;	
  Azakir	
  et	
  al.,	
  2010;	
  Matsuda	
  et	
  al.,	
  2012).	
  We	
  reason	
  that	
  the	
  mini-­‐dysferlin	
  molecules	
  described	
  in	
  Chapter	
  3,	
  which	
  contain	
  the	
  C2A,	
  C2F	
  and/or	
  C2G	
  domains,	
  may	
  be	
  better	
  suited	
  for	
  AAV-­‐mediated	
  gene	
  therapy.	
  	
  	
  	
  One	
  advantage	
  AAV-­‐mediated	
  gene	
   therapy	
  has	
  over	
  exon	
  skipping	
   is	
   that	
   it	
  does	
  not	
  require	
   tailoring	
   to	
   each	
   patient’s	
   mutation(s).	
   However,	
   studies	
   are	
   required	
   to	
  determine	
  whether	
  the	
  mini-­‐dysferlins	
  described	
  in	
  Chapter	
  3	
  would	
  be	
  able	
  to	
  alleviate	
  the	
  dystrophic	
  features.	
  Lostal	
  et	
  al	
  pointed	
  out	
  that	
  in	
  vitro	
  resealing	
  assays	
  might	
  not	
  fully	
   reflect	
   the	
   ability	
   of	
   a	
   dysferlin	
   construct	
   to	
   reverse	
   or	
   improve	
   the	
   in	
   vivo	
  dystrophic	
  phenotype	
  (Lostal	
  et	
  al.,	
  2012).	
  This	
  emphasizes	
  the	
  fact	
  that	
  although	
  loss	
  of	
   membrane	
   repair	
   capabilities	
   in	
   dysferlin-­‐deficient	
   muscle	
   is	
   an	
   essential	
   role	
   of	
  dysferlin,	
  it	
  may	
  not	
  be	
  the	
  only	
  role	
  or	
  the	
  only	
  contributing	
  factor	
  to	
  the	
  development	
  of	
   dystrophic	
   muscles.	
   Studies	
   on	
   dysferlin-­‐deficient	
   human	
   and	
   mouse	
  muscle/cultured	
  muscle	
  cells/monocytes	
  point	
  towards	
  other	
  influencing	
  factors,	
  such	
  as	
  the	
  upregulation	
  of	
  the	
  inflammasome	
  and	
  its	
  activation	
  (Rawat	
  et	
  al.,	
  2010),	
  which	
  includes	
  (among	
  others)	
  the	
  upregulation	
  of	
  Thrombospondin-­‐1	
  (De	
  Luna	
  et	
  al.,	
  2010)	
  and	
   pro-­‐inflammatory	
   NFκB	
   signaling	
   (Cohen	
   et	
   al.,	
   2012),	
   increased	
   monocyte	
  phagocytosis	
   (Nagaraju	
   et	
   al.,	
   2008),	
   increased	
   dendritic	
   cell-­‐T	
   cell	
   activation	
   via	
   the	
  inadvertent	
   release	
   of	
   co-­‐stimulatory	
   signals	
   from	
   the	
   compensatory	
   Rab27A/Slp2a	
  endocytosic	
  trafficking	
  in	
  muscle	
  cells	
  (Kesari	
  et	
  al.,	
  2008)	
  and	
  increased	
  expression	
  of	
  complement	
  factors	
  (Han	
  et	
  al.,	
  2010).	
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A	
  standard	
  concern	
  for	
  gene	
  therapy	
  is	
  possible	
  immunogenicity	
  from	
  the	
  gene	
  delivery	
  system.	
  AAV	
  ensures	
  the	
  lowest	
  immunogenicity	
  of	
  the	
  viral	
  vectors;	
  however,	
  several	
  human	
   clinical	
   trials	
   with	
   AAV	
   revealed	
   that	
   the	
   host’s	
   immune	
   system	
   generates	
  antibodies	
  against	
  the	
  AAV	
  vector	
  used	
  (Manno	
  et	
  al.,	
  2006;	
  Mingozzi	
  et	
  al.,	
  2007;	
  Sterz	
  et	
   al.,	
   2008),	
   which	
   precludes	
   the	
   effectiveness	
   of	
   any	
   subsequent	
   injections.	
   Similar	
  effects	
  have	
  been	
  reported	
  in	
  canine	
  Duchenne	
  muscular	
  dystrophy	
  studies,	
  but	
  a	
  short	
  course	
   of	
   immunosuppression	
   was	
   sufficient	
   to	
   allow	
   long-­‐term	
   expression	
   of	
   the	
  recombinant	
   protein	
   (Wang	
   et	
   al.,	
   2007;	
  Wang	
   et	
   al.,	
   2007).	
   Studies	
   are	
   ongoing	
   into	
  modifying	
  AAV	
  serotypes	
  to	
  be	
  less	
  immunogenic	
  or	
  to	
  contain	
  the	
  combined	
  features	
  of	
  two	
  different	
  serotypes	
  (Evans	
  et	
  al.,	
  2008;	
  Koo	
  et	
  al.,	
  2011;	
  Bowles	
  et	
  al.,	
  2012).	
  There	
  are	
  also	
  concerns	
  that	
  the	
  introduction	
  of	
  a	
  dysferlin	
  protein	
  that	
  is	
  essentially	
  novel	
  to	
  the	
   dysferlinopathic	
   system	
   may	
   result	
   in	
   an	
   immune	
   response	
   against	
   the	
   ‘foreign’	
  protein.	
  	
  	
  
6.1.3 Wildtype	
  and	
  missense	
  mutated	
  dysferlin	
  are	
  degraded	
  in	
  the	
  proteasome	
  	
  
Objective	
   IV	
   –	
   To	
   determine	
   the	
   degradation	
   pathway(s)	
   of	
   wildtype	
   dysferlin	
   and	
  
missense-­‐mutated	
  dysferlin.	
  	
  At	
  the	
  onset	
  of	
  this	
  thesis,	
  dysferlin’s	
  degradation	
  pathway	
  was	
  not	
  fully	
  characterized.	
  One	
  study	
  determined	
  that	
  dysferlin	
  is	
  a	
  short-­‐lived	
  protein,	
  with	
  a	
  half-­‐life	
  of	
  four	
  to	
  six	
  hours	
   (Evesson	
   et	
   al.,	
   2010).	
   The	
   authors	
   suggested	
   that	
   missense-­‐mutated	
  (Leu344Pro)	
  dysferlin	
  and	
  dysferlin∆C2C	
  were	
  degraded	
  by	
  ER-­‐associated	
  degradation	
  (ERAD)	
  via	
  the	
  ubiquitin-­‐proteasome	
  system;	
  however,	
  the	
  data	
  presented	
  in	
  that	
  paper	
  was	
  difficult	
  to	
  interpret.	
  Another	
  study	
  proposed	
  that	
  wildtype	
  dysferlin	
  was	
  primarily	
  degraded	
   by	
   the	
   ERAD	
   ubiquitin-­‐proteasome	
   system,	
   whereas	
   a	
   missense-­‐mutated	
  (Leu1341Pro)	
  dysferlin	
  was	
  degraded	
  by	
  both	
  the	
  ubiquitin-­‐proteasome	
  system	
  and	
  the	
  autophagy-­‐lysosomal	
   system	
   (Fujita	
   et	
   al.,	
   2007).	
  However,	
   this	
   study	
  was	
  performed	
  using	
  an	
  overexpression	
  system,	
  which	
  likely	
  caused	
  non-­‐physiological	
  ‘overflow’	
  from	
  the	
  ERAD	
  system	
  into	
  the	
  lysosomal	
  pathway.	
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In	
  Chapter	
  4	
  of	
   this	
   thesis,	
  we	
  showed	
   that	
  both	
  endogenous	
   full-­‐length	
  dysferlin	
  and	
  endogenous	
  missense-­‐mutated	
   Arg555Trp	
   are	
   degraded	
   by	
   the	
   ubiquitin-­‐proteasome	
  system,	
  and	
  are	
  not	
  degraded	
  by	
  the	
  lysosomal	
  system	
  to	
  a	
  detectable	
  degree.	
  	
  	
  	
  
6.1.3.1 Therapeutic	
  potential	
  of	
  proteasomal	
  inhibitors	
  for	
  dysferlinopathies	
  	
  The	
   study	
   presented	
   in	
   Chapter	
   4	
   offers	
   proof-­‐of-­‐principle	
   for	
   the	
   potential	
   of	
  proteasomal	
  inhibition	
  as	
  a	
  novel	
  treatment	
  strategy	
  for	
  dysferlinopathies.	
  	
  	
  Velcade	
   (registered	
   name	
   for	
   bortezomib)	
   is	
   a	
   Federal	
   Drug	
   Administration	
   (FDA)-­‐approved	
   drug	
   currently	
   in	
   clinical	
   use	
   for	
   the	
   treatment	
   of	
   multiple	
   myelomas	
   and	
  mantle	
  cell	
  lymphoma	
  (Adams,	
  2004;	
  Bross	
  et	
  al.,	
  2004).	
  In	
  multiple	
  myelomas,	
  Velcade	
  selectively	
  induces	
  apoptosis	
  of	
  cancer	
  cells	
  by	
  preventing	
  the	
  degradation	
  of	
  proteins	
  implicated	
   in	
  cell	
  cycle	
  control	
  and	
  surival,	
  such	
  as	
  the	
  NF-­‐kB	
  inhibitor,	
   IkB	
  (Obeng	
  et	
  al.,	
   2006).	
   NF-­‐kB	
   is	
   a	
   transcription	
   factor	
   that	
   promotes	
   cell	
   survival	
   and	
   cell	
  proliferation.	
  Cancers	
  prefer	
   to	
  degrade	
   IkB,	
   thus	
  keeping	
  NF-­‐kB	
  constitutively	
  active.	
  The	
  proteasomal	
  inhibitor,	
  Velcade,	
  stabilizes	
  IkB,	
  thus	
  promoting	
  cancer	
  cell	
  apoptosis.	
  	
  	
  	
  Multiple	
   myeloma	
   cells	
   are	
   particularly	
   sensitive	
   to	
   Velcade	
   treatment.	
   The	
  antineoplastic	
  doses	
  used	
  for	
  multiple	
  myeloma	
  treatment	
  were	
  shown	
  to	
  be	
  too	
  low	
  to	
  affect	
   normal	
   cells	
   (Hideshima	
   et	
   al.,	
   2001).	
   These	
   doses	
   correlate	
   with	
   the	
   Velcade	
  concentrations	
  used	
  to	
  promote	
  dysferlin	
  rescue	
  from	
  proteasomal	
  degradation	
  used	
  in	
  Chapter	
   4.	
   Velcade	
   concentrations	
   that	
   allowed	
   for	
   rescued	
   membrane	
   repair	
   and	
  myoblast	
   fusion	
  (10	
  nM)	
  were	
  not	
   toxic	
  even	
  when	
  cells	
  were	
  treated	
   for	
  5	
  days.	
   It	
   is	
  therefore	
   possible	
   that	
   concentrations	
   of	
   Velcade	
   similar	
   to	
   those	
   used	
   for	
   the	
  treatment	
  of	
  patients	
  with	
  multiple	
  myeloma	
  would	
  also	
   influence	
   the	
  degradation	
  of	
  missense	
  mutated	
  dysferlin.	
  	
  	
  Proteasomal	
   inhibition	
   has	
   also	
   been	
   proposed	
   for	
   other	
   diseases	
   caused	
   by	
   point	
  mutations.	
  In	
  cystic	
  fibrosis,	
  the	
  chloride	
  channel	
  protein	
  bears	
  the	
  mutation	
  ∆F508	
  (a	
  single	
   nucleotide	
   deletion)	
   (Ward	
   et	
   al.,	
   1995),	
   causing	
   it	
   to	
   be	
   retained	
   in	
   the	
  endoplasmic	
   reticulum	
   and	
   subsequently	
   degraded.	
   However,	
   treatment	
   with	
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proteasomal	
   inhibition	
   demonstrated	
   that	
   the	
   mutated	
   protein	
   preserved	
   its	
  functionality	
  when	
  allowed	
  to	
  reach	
  the	
  plasma	
  membrane	
  (Pedemonte	
  et	
  al.,	
  2005).	
  A	
  similar	
   scenario	
   is	
   observed	
   when	
   missense	
   mutated	
   caveolin-­‐3	
   is	
   freed	
   from	
   its	
  sequestration	
   at	
   the	
   Golgi	
   apparatus	
   and	
   permitted	
   to	
   reach	
   the	
   plasma	
   membrane	
  (Galbiati	
   et	
   al.,	
   2000).	
   These	
   examples	
   lend	
   credence	
   to	
   the	
   possibility	
   of	
   treating	
  missense	
  mutated	
  dysferlin	
  with	
  proteasomal	
  inhibitors.	
  	
  	
  However,	
  the	
  results	
  of	
  Chapter	
  5	
  suggest	
  that	
  not	
  all	
  patients	
  would	
  benefit	
  from	
  this	
  treatment,	
   as	
   suggested	
   by	
   the	
   Arg959Trp,	
   Pro1970Ser	
   and	
   Arg2042Cys	
   missense	
  mutations.	
   Patients	
   would	
   first	
   have	
   to	
   be	
   screened	
   to	
   ascertain	
   if	
   their	
   mutation(s)	
  would	
  be	
  benefitted	
  by	
  Velcade	
  treatment,	
  most	
   likely	
  by	
   in	
  vitro	
  membrane	
  resealing	
  assays	
  performed	
  on	
  cultured	
  biopsy-­‐derived	
  myoblasts.	
  	
  	
  
6.1.4 Certain	
  dysferlin	
  missense	
  mutations	
  are	
  intrinsically	
  biologically	
  active	
  
	
  
Objective	
   V	
   –	
   To	
   determine	
   whether	
   missense-­‐mutated	
   dysferlin	
   retains	
   its	
   biological	
  
activity,	
  despite	
  being	
  flagged	
  for	
  degradation	
  by	
  the	
  cell’s	
  quality	
  control	
  system.	
  	
  	
  	
  It	
   is	
  believed	
  that	
  dysferlin	
   is	
  very	
  sensitive	
   to	
  single	
  point	
  mutations,	
  given	
  that	
   they	
  account	
   for	
   71%	
   of	
   DYSF	
   mutations	
   and	
   result	
   in	
   loss	
   of,	
   or	
   severe	
   reduction	
   in,	
  dysferlin	
   protein	
   levels.	
   A	
   study	
   revealed	
   that	
   the	
   missense	
   mutation	
   Leu344Pro	
  showed	
   increased	
   protein	
   internalization	
   from	
   the	
   plasma	
   membrane	
   (~1.5	
   hours,	
  compared	
   to	
   3	
   hours	
   for	
   wildtype	
   dysferlin)	
   and	
   increased	
   protein	
   lability	
   when	
  compared	
   to	
   wildtype	
   dysferlin	
   (Evesson	
   et	
   al.,	
   2010).	
   This	
   suggests	
   that	
   missense-­‐mutated	
  dysferlin	
  is	
  rapidly	
  degraded	
  by	
  the	
  ubiquitin-­‐proteasome	
  system.	
  However,	
  it	
  was	
   uncertain	
   whether	
   missense	
   mutated	
   dysferlin	
   was	
   degraded	
   because	
   it	
   was	
  nonfunctional	
   or	
   because	
   it	
   was	
   too	
   quickly	
   recognized	
   by	
   the	
   cell’s	
   quality	
   control	
  system.	
  	
  	
  	
  In	
   Chapter	
   4,	
   we	
   presented	
   a	
   dysferlin	
   missense	
   mutation	
   (Arg555Trp)	
   that,	
   upon	
  salvage	
  from	
  proteasomal	
  degradation,	
  demonstrated	
  biological	
  activity;	
  it	
  rescued	
  the	
  membrane-­‐resealing	
   deficit,	
   restored	
   plasmalemmal	
   localization	
   and	
   rescued	
   the	
  impairment	
   in	
   myotube	
   formation.	
   Study	
   of	
   additional	
   dysferlin	
   missense	
   mutation-­‐
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harbouring	
   constructs	
   revealed	
   that	
   this	
   is	
   not	
   a	
   solitary	
   case:	
   dysferlin	
   missense	
  mutations	
   Val374Leu	
   and	
   Asp1837Asn	
   also	
   demonstrated	
   intrinsic	
   functionality,	
   as	
  they	
   were	
   able	
   to	
   restore	
   membrane	
   resealing	
   kinetics	
   in	
   dysferlin-­‐deficient	
   muscle	
  cells.	
   Furthermore,	
   they	
   demonstrated	
   correct	
   plasmalemmal	
   localization	
   when	
  expressed	
  in	
  dysferlin-­‐deficient	
  muscle	
  cells.	
  	
  These	
  constructs	
  did	
  not	
  require	
  proteasomal	
  inhibitor	
  treatment	
  to	
  demonstrate	
  these	
  functions,	
  as	
  was	
  required	
   in	
   the	
  patient-­‐derived	
  muscle	
  cell	
   line.	
  This	
   is	
   likely	
  due	
  to	
  the	
  use	
  of	
  an	
  overexpression	
  system:	
  the	
  amount	
  of	
  exogenous	
  protein	
  produced	
  by	
  the	
  transfected	
   plasmids	
   far	
   exceeded	
   the	
   amount	
   of	
   endogenous	
   protein	
   salvaged	
   by	
  Velcade	
   treatment	
   in	
   the	
   patient-­‐derived	
   muscle	
   cell	
   line.	
   This	
   suggests	
   that	
   if	
   the	
  protein	
   can	
   escape	
   the	
   cell’s	
   quality	
   control	
   system,	
   certain	
   missense	
   mutations	
   can	
  correctly	
  perform	
  their	
  functions	
  (plasmalemmal	
  localization	
  and	
  membrane	
  repair,	
  at	
  least),	
   as	
   they	
   are	
   intrinsically	
   biologically	
   active.	
   This	
   suggests	
   that	
   one	
   needs	
   to	
  increase	
  the	
  dysferlin	
  protein	
  level	
  to	
  a	
  sufficient	
  threshold	
  for	
  it	
  to	
  have	
  a	
  measurable	
  effect	
  on	
  functional	
  outcome	
  measures;	
  Lostal	
  et	
  al	
  propose	
  that	
  10%	
  dysferlin	
  levels	
  at	
  the	
  sarcolemma	
  is	
  sufficient	
   for	
  normal	
  membrane	
  resealing	
  (Lostal	
  et	
  al.,	
  2010).	
  This	
  expression	
  level	
  is	
  far	
  surpassed	
  by	
  the	
  transfection	
  levels	
  achieved	
  in	
  this	
  study.	
  	
  	
  
6.1.5 Not	
  all	
  dysferlin	
  missense	
  mutations	
  are	
  intrinsically	
  biologically	
  active	
  	
  Not	
   all	
   dysferlin	
  missense	
  mutations	
   are	
   intrinsically	
   active,	
   as	
   demonstrated	
   by	
   the	
  Arg959Trp,	
   Pro1970Ser	
   and	
   Arg2042Cys	
   missense	
   mutated	
   constructs.	
   Even	
   when	
  overexpressed	
   in	
   dysferlin-­‐deficient	
   muscle	
   cells,	
   these	
   mutations	
   were	
   unable	
   to	
  rescue	
   membrane	
   resealing	
   kinetics,	
   nor	
   localize	
   correctly	
   at	
   the	
   plasma	
   membrane	
  (except	
   for	
   Arg2042Cys),	
   regardless	
   of	
   Velcade	
   treatment.	
   These	
   three	
   mutated	
  constructs	
   validate	
   the	
   studies	
   performed	
   in	
   Chapter	
   5,	
   showing	
   that	
   increasing	
  dysferlin	
  levels	
  is	
  not	
  sufficient	
  to	
  show	
  protein	
  activity	
  of	
  missense	
  mutated	
  dysferlin.	
  These	
  studies	
  also	
  demonstrate	
  that	
  proteasomal	
  inhibitor	
  treatment	
  would	
  not	
  benefit	
  all	
  dysferlin-­‐deficient	
  patients,	
  and	
  suggest	
  that	
  personalized	
  screening	
  of	
  each	
  patient’s	
  mutation(s)	
  would	
  be	
  needed	
  to	
  assess	
  the	
  applicability	
  of	
  proteasomal	
  inhibition	
  as	
  a	
  beneficial	
  treatment	
  option.	
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6.2 Outlook	
  	
  The	
  two	
  functional	
  mini-­‐dysferlins	
  presented	
  in	
  Chapter	
  3	
  are	
  currently	
  being	
  examined	
  in	
  a	
  gene	
  therapy	
  study	
  using	
  a	
  mouse	
  model	
  of	
  dysferlinopathy	
  in	
  our	
  laboratory.	
  This	
  will	
   assess	
   whether	
   these	
   mini-­‐dysferlins	
   can	
   ameliorate	
   the	
   muscular	
   dystrophy	
  phenotype	
  present	
  in	
  these	
  mice.	
  	
  	
  Swiss	
   Medic	
   has	
   approved	
   the	
   proof-­‐of-­‐concept	
   study	
   presented	
   in	
   Chapter	
   4	
   for	
   a	
  clinical	
  trial	
  study	
  to	
  assess	
  whether	
  Velcade	
  administration	
  increases	
  dysferlin	
  protein	
  levels	
   in	
   skeletal	
   muscle	
   of	
   dysferlinopathy	
   patients	
   harbouring	
   the	
   Arg555Trp	
  mutation.	
  These	
  trials	
  represent	
  the	
  first	
  dysferlin-­‐directed	
  therapeutic	
  option	
  available	
  to	
   patients	
   with	
   dysferlin	
   deficiency.	
   To	
   decrease	
   the	
   side	
   effects	
   of	
   proteasomal	
  inhibition,	
   our	
   research	
   group	
   is	
   pursuing	
   the	
   identification	
   and	
   inhibition	
   of	
   the	
   E3	
  ubiquitin	
   ligase(s)	
   that	
   targets	
   dysferlin	
   for	
   proteasomal	
   degradation.	
   Our	
   research	
  group	
   will	
   continue	
   to	
   characterize	
   the	
   functionality	
   of	
   common	
   dysferlin	
   missense	
  mutations,	
   in	
   order	
   to	
   increase	
   the	
   list	
   of	
   number	
   of	
   patients	
  who	
  may	
   be	
   helped	
   by	
  Velcade	
   treatment.	
  These	
   characterization	
   studies	
   could	
  also	
  open	
   the	
   field	
   to	
   further	
  investigation	
  into	
  dysferlin’s	
  molecular	
  biology,	
  to	
  provide	
  new	
  insights	
  into	
  dysferlin’s	
  structure,	
  stability	
  and	
  lipid/protein	
  interactions.	
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